TY - CHAP
T1 - Advances in diagnosis and management of secondary and tertiary hyperparathyroidism
AU - van der Plas, Willemijn Y.
AU - Vogt, Liffert
AU - Kruijff, Schelto
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Hyperparathyroidism is a common complication of end-stage renal disease (ESRD). Secondary hyperparathyroidism (HPT) is characterized by increased parathyroid hormone (PTH) levels in combination of hypocalcemia and hyperphosphatemia in the presence of ESRD. In tertiary HPT, patients have increased PTH levels, as well as hypercalcemia and hyperphosphatemia, due to a disturbed feedback system after prolonged period of secondary HPT. Diagnosis is established by the measurement of serum PTH, calcium, phosphate, and vitamin D concentrations multiple times over a longer period of time. Treatment options include vitamin D supplements, phosphate binders, calcimimetics, and parathyroidectomy.
AB - Hyperparathyroidism is a common complication of end-stage renal disease (ESRD). Secondary hyperparathyroidism (HPT) is characterized by increased parathyroid hormone (PTH) levels in combination of hypocalcemia and hyperphosphatemia in the presence of ESRD. In tertiary HPT, patients have increased PTH levels, as well as hypercalcemia and hyperphosphatemia, due to a disturbed feedback system after prolonged period of secondary HPT. Diagnosis is established by the measurement of serum PTH, calcium, phosphate, and vitamin D concentrations multiple times over a longer period of time. Treatment options include vitamin D supplements, phosphate binders, calcimimetics, and parathyroidectomy.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090943990&origin=inward
U2 - https://doi.org/10.1016/B978-0-323-66195-9.00008-X
DO - https://doi.org/10.1016/B978-0-323-66195-9.00008-X
M3 - Chapter
SN - 9780323661942
T3 - Advances in Treatment and Management in Surgical Endocrinology
SP - 85
EP - 99
BT - Advances in Treatment and Management in Surgical Endocrinology
PB - Elsevier
ER -